AdvanTIG-301: a phase III study of ociperlimab plus tislelizumab and concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer.
- DOI
- 10.1136/jitc-2025-013527
- Published
- 2026 Aug 26
- Container
- Journal for immunotherapy of cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/jitc-2025-013527,
title = {AdvanTIG-301: a phase III study of ociperlimab plus tislelizumab and concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer.},
author = {Xing L and Kato T and Levy A and Loo BW Jr and Spira AI and Wang J and Meng X and Pang Q and Badin F and Wang H and Dómine Gómez M and Wang Y and Chen Y and Yao B and Yang L and Yu J and Peters S},
year = {2026},
journal = {Journal for immunotherapy of cancer},
doi = {10.1136/jitc-2025-013527},
url = {https://doi.org/10.1136/jitc-2025-013527}
}RIS
TY - JOUR TI - AdvanTIG-301: a phase III study of ociperlimab plus tislelizumab and concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer. AU - Xing L AU - Kato T AU - Levy A AU - Loo BW Jr AU - Spira AI AU - Wang J AU - Meng X AU - Pang Q AU - Badin F AU - Wang H AU - Dómine Gómez M AU - Wang Y AU - Chen Y AU - Yao B AU - Yang L AU - Yu J AU - Peters S PY - 2026 JO - Journal for immunotherapy of cancer DO - 10.1136/jitc-2025-013527 UR - https://doi.org/10.1136/jitc-2025-013527 ER -
APA
L, X., T, K., A, L., Jr, L. B., AI, S., J, W., X, M., Q, P., F, B., H, W., M, D. G., Y, W., Y, C., B, Y., L, Y., J, Y., & S, P. (2026). AdvanTIG-301: a phase III study of ociperlimab plus tislelizumab and concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2025-013527
Source records
- pubmed · retrieved 2026-09-25T12:49:11.571Z